Data as of Dec 05
| -0.04 / -1.41%|
pSivida Corp. develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate. It currently focuses on treatment of chronic diseases of the back of the eye utilizing its core technology systems, Durasert and BioSilicon. The company offers Vitrasert, Retisert, Iluvien, BioSilicon, Iluvien (Dry-AMD), Iluvien (Wet-AMD), Iluvien (Retinal Vein Occlusion), Duraset/Latanoprost and BioSilicon Technology. Its lead development product, Iluvien delivers the steroid fluocinolone acetonide for the treatment of diabetic macular edema, one of the leading causes of blindness. The company was founded by Roger Aston in March 2008 and is headquartered in Waterson, MA.
|Paul Ashton||President, Chief Executive Officer & Director|
|Marty Nazzaro||Vice President-Operations|
|Leonard S. Ross||VP, Chief Financial & Accounting Officer|
|Hong Guo||Vice President-Research|
|Lori H. Freedman||Secretary, VP-Corporate Affairs & General Counsel|